Primary Angioplasty for Acute Myocardial Infarction in Patients With Symptom Duration Above 12 Hours
|ClinicalTrials.gov Identifier: NCT00260416|
Recruitment Status : Completed
First Posted : December 1, 2005
Last Update Posted : May 22, 2008
Background: Acute balloon angioplasty is beneficial in patients with acute myocardial infarction. However, presently this treatment is not offered to patients with symptom duration above 12 hours.
Hypothesis: Acute balloon angioplasty for myocardial infarction is beneficial despite symptom duration above 12 hours.
Methods: In 60 patients with myocardial infarction and symptom duration above 12 hours, the proportion of non-perfused myocardium before acute angioplasty and 1 month after angioplasty is compared to evaluate if myocardial tissue can be saved by acute angioplasty despite long symptom duration.
|Condition or disease||Intervention/treatment||Phase|
|Acute Myocardial Infarction||Procedure: Primary angioplasty with stent and abciximab||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Primary Angioplasty for Acute Myocardial Infarction in Patients With Symptom Duration Above 12 Hours|
|Study Start Date :||May 2005|
|Actual Primary Completion Date :||December 2007|
|Actual Study Completion Date :||December 2007|
- Myocardial salvage as evaluated by repeat myocardial scintigraphy(= area at risk of infarction before primary angioplasty - infarct size at 1 month).
- Infarct size by myocardial scintigraphy at 1 month and 6 months after primary angioplasty.
- Death at 1 month and 6 months.
- Reinfarction at 1 month and 6 months.
- Ejection fraction at 1 day, 1 month and 6 months.
- Left ventricular end diastolic volume at 1 day, 1 month and 6 months.
- Brain Natriuretic Peptide levels at 1 day, 1 month and 6 months.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00260416
|Departments of Cardiology and Nuclear Medicine at Skejby Hospital|
|Aarhus, Denmark, DK-8200 N|
|Study Director:||Steen D. Kristensen, MD||Dept. of Cardiology, Skejby Hospital, AarhusUniversity Hospital, DK-8200 Aarhus N, Denmark, Europe|